CD8A and myeloid sarcoma: Our finding of decreased CD8+ T cell reactivity to LCL in patients with MS [15] differs from a previous small study on 11 patients which reported a non-significant increase in the frequency of LCL-specific CD8+ T cells [17], but is consistent with an early report of decreased T cell control of LCL outgrowth [18] and a recent report of a trend (p = 0.07) towards a decreased CD8+ T cell response to LCL [19].